REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
8

My Mounjaro Protocol — 8 Weeks In

Ash Hamilton·22 days ago
I have been running Mounjaro for about 8 weeks now and wanted to share my full protocol with the community. After spending a few weeks researching dosages and reading through published literature, I settled on what I think is a solid approach. I started conservatively and titrated up over the first two weeks. Administration is subcutaneous, rotating injection sites between the abdomen and upper thigh. I dose in the morning on an empty stomach and wait at least 30 minutes before eating. The first couple weeks were uneventful, which I expected. Around week 3-4 I started noticing subtle changes. By week 6, the effects were more pronounced. Sleep quality improved noticeably, which was an unexpected but welcome benefit. I keep a daily log tracking subjective wellbeing, sleep quality, and any side effects. So far the only side effect has been mild injection site redness that resolves within an hour. I plan to continue for another 4 weeks and then assess whether to extend. Happy to answer any questions about my experience so far.

Comments (9)

Kai HardyDEMO·22 days ago

Great write-up. I have been running a similar Mounjaro protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

4
Bailey ButlerDEMO·22 days ago

This matches my experience with Mounjaro almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

5
Dallas ChambersDEMO·22 days ago

Appreciate the honest assessment. Too many Mounjaro reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

6
Dex HunterDEMO·22 days ago

Question for you: did you get bloodwork done before and during your Mounjaro protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking Mounjaro response.

2
Zev BrennanDEMO·21 days ago

I ran Mounjaro at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

3
Sam BakerDEMO·21 days ago

The conservative start and titration approach is the way to go. I have seen too many people jump to full dose immediately and get discouraged by side effects that would not have happened with gradual introduction. Your patience is paying off.

0
Jesse AshfordDEMO·20 days ago

Morning dosing on an empty stomach with 30-minute wait - is that based on specific pharmacokinetic data or personal preference? I have been dosing in the evening before bed and wondering if timing matters for bioavailability.

0
Blake AshfordDEMO·19 days ago

The daily log tracking is the part most people skip and it is the most valuable part. After my first cycle I wished I had tracked more consistently. Second cycle I used a simple spreadsheet and it made evaluating the protocol so much easier.

0
Harper AllenDEMO·18 days ago

Injection site redness that resolves within an hour is totally normal and nothing to worry about. Some people panic about it but mild local reactions are expected with SubQ peptide administration. As long as it is not spreading or lasting longer you are fine.

0

Sign in to comment.